Pattern Data Commons totals as of Sept 30, 2026. Patients and samples are distinct IDs across datasets.
Collect once. Clean once. Analyze many times.
Most of the time in data science goes to hunting for errors that crept in at integration. UnifyBio moves that work to the front, where it is cheap, mechanical and reviewable.
Declare it, don't hard-code it
Annotate a Datomic schema with the Unify metamodel. Imports are then inferred from the schema, and the same tools work for new domains.
Precise, mechanical feedback
Bad references, out of range measurement values, and gaps in data stop the import. Precise feedback lets humans and coding agents fix and rerun in seconds to minutes.
Reproduce any analysis
Every query has a time basis and an audit trail back to raw data. Rerun an old query as of any point in time.
Change the model, keep the tools
Import, query and visualization tools introspect the schema from the database. New schema doesn't require code changes.
Fit whatever comes next
The store can project data into whatever shape you need. Give each downstream tool the data it expects without 'munging'.
Built from CANDEL
Built on tooling open-sourced by the Parker Institute for Cancer Immunotherapy. Designed from day one to be schema-agnostic.
Thoughtfully engineered by humans, for humans
Now AI provides massive leverage at the edges of the system.
Preprocess. Import. Validate. Fix. Repeat.
Each pass takes minutes and leaves an artifact you can review. Once harmonization is done, the agents can be dispensed with. Downstream analysis queries clean data instead of a pile of sed, awk and one-off scripts.
A schema that adapts to every new patient, sample, and assay it sees
The Pattern Schema (v0.3.8 shown) has 43 kinds, from subjects and timepoints to measurements and single cells. Teal kinds hold data, amber kinds are shared reference vocabularies such as genes, proteins and drugs. Click any kind to open its page in the schema browser.
Assays in the latest schema (v0.3.9)
One philosophy, from a single patient to a whole commons.
The Pattern Data Commons harmonizes patient-donated datasets, straight from the firehose of EHR and raw FASTQ, into a common schema alongside more than 50 public datasets. Unify Central serves it from a deliberately simple Clojure and Datomic monolith. Because the data is harmonized, queries stay small and the UI is server-rendered HTML.
Multiple molecular data types and clinical sources live in one model, linked by shared identifiers and dataset context-specific identity resolution.
- Hypermedia, not framework sprawl. Clojure, Datomic, hiccup and HTMX. The server renders, and declarative attributes drive the interactivity.
- Every dataset is its own database. Datasets stay independent and versioned, and they are still comparable across studies.
- Queries are plain JSON. Any language can call the query API, and the client libraries below make that easy.
- Shims, not rewrites. Targeted projections turn the harmonized core into whatever a UI or analysis needs.
The same catalog, in four languages.
The patternq family shares one function catalog, the same result columns and the same plots. Work in the language your team already uses.
import patternq as pq import patternq.dataset as pqd import patternq.survival as pqs # every dataset is its own database pq.set_db(pq.resolve_db("prince-2022")) pqd.dataset_summary() outcomes = pqd.subject_outcomes() # BOR / PFS / OS pqd.variants(genes=["KRAS", "TP53"]) pqd.gene_expression(genes=["CXCL9"], measurement="tpm")
Harmonized data, real results.
Publications
- Padrón LJ, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine 28(6):1167-1177 (2022).
- O’Hara MH, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology 22(1):118-131 (2021).
- Quandt Z, Lucas A, Liang SI, et al. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. Journal for ImmunoTherapy of Cancer 13(5):e011545 (2025).
- Tsimberidou AM, et al. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Journal of Experimental Medicine 221(10):e20240152 (2024).
- Campbell KM, et al. Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. Cancer Discovery 16(9) (2026).
- Glitza IC, et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discovery 14(7):1161-1175 (2024).
- O’Reilly EM, et al. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for ImmunoTherapy of Cancer 14(1):e012864 (2026).
- Galsky MD, et al. Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer. Clinical Cancer Research 31(8):1463-1475 (2025).
Abstracts & posters
- Smith A, Kamphaus B, et al. Patient-driven multi-omic longitudinal research study reveals novel insights into uveal melanoma progression. Cancer Research 86(7 Suppl):2514 (2026). AACR Annual Meeting.
- Kamphaus BD, McQuade JL, Littleford HE, Kageyama R, Scales JL, Spencer CN, Thompson MA. Patient-driven N-of-1 longitudinal multi-omic study of uveal melanoma identifies functional loss of BAP1 VUS and evolving tumor-immune dynamics. Cancer Research, Abstract B044 (2026).
- Lucas A, Liang S, Da Silva D, Young A, Quandt Z, Boffo S, et al. Relationships between irAEs and checkpoint inhibitor response in RADIOHEAD: a large prospective pan-tumor cohort of standard-of-care patients with clinical annotation, molecular and immune profiling. Journal for ImmunoTherapy of Cancer 10(Suppl 2):1256 (2022). SITC.
- Healy CP, Sweere JM, Liang SI, et al. Immune features of irAEs and aPD1 response in urothelial cancer patients of the RADIOHEAD study, as detected in blood by mass cytometry immune profiling. Cancer Research 83(7 Suppl):2138 (2023). AACR Annual Meeting.
- Alayli F, et al. AMADEUS trial: tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration. Journal for ImmunoTherapy of Cancer 10(Suppl 2):587 (2022). SITC.
- Galsky M, et al. Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients. Journal for ImmunoTherapy of Cancer 10(Suppl 2):555 (2022). SITC.
- Lyman J, et al. Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION). Journal for ImmunoTherapy of Cancer 10(Suppl 2):656 (2022). SITC.
- Padrón LJ, et al. Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 40(16 Suppl):4010 (2022). ASCO.
- O’Reilly EM, et al. Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology 42(16 Suppl):4137 (2024). ASCO.
- Maxey J, Thompson M, Campbell K, Kamphaus B, et al. A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumor-immune microenvironment. Journal for ImmunoTherapy of Cancer 10(Suppl 2):1292 (2022). SITC.
- Glitza Oliva I, et al. MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients. Journal for ImmunoTherapy of Cancer 10(Suppl 2):607 (2022). SITC.
UnifyBio derives and declares the shape, checks every import mechanically, and leaves you a time-auditable store of record that people and algorithms can both query.